Jyong Biotech Stock (NASDAQ:MENS)
Previous Close
$1.88
52W Range
$1.43 - $67.00
50D Avg
$2.02
200D Avg
$16.64
Market Cap
$167.26M
Avg Vol (3M)
$110.10K
Beta
2.08
Div Yield
-
MENS Company Profile
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
MENS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AAPG | Ascentage Pharma Group International |
| TVTX | Travere Therapeutics, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |
| CELC | Celcuity Inc. |
| CGON | CG Oncology Inc. |
| XENE | Xenon Pharmaceuticals Inc. |
| DYN | Dyne Therapeutics, Inc. |
| LEGN | Legend Biotech Corporation |
| CNTA | Centessa Pharmaceuticals plc |
| APGE | Apogee Therapeutics, Inc. |